EED and cancer: Based on a clinical EZH2 inhibitor EPZ6438 and pomalidomide, Yu group developed the degrader 154 (E7, Fig. 37) which induced degradation efficacies of all PRC subunits(EZH2 72%, SUZ12 81%, EED 75%, RbAp48 74%) at 1 μM in WSU-DLCL-2 cells.264 The degrader 154 (E7) also displayed stronger anticancer abilities than EPZ6438 in WSU-DLCL-2 cells and SWI/SNF-mutant cancer cells.